October 2012

National Institute of Nutrition (NIN) was founded by Sir Robert McCarrison in the year 1918 as ‘Beri-Beri’ Enquiry Unit in a single room laboratory at the Pasteur Institute, Coonoor, Tamil Nadu.

Spices Board (Ministry of Commerce, Government of India) is the flagship organization for the development and worldwide promotion of Indian spices. The Board is an international link between the Indian exporters and the importers abroad. The Board has been spearheading activities for excellence of Indian spices, involving every segment of the industry. The Board has made quality and hygiene the corner stones for its development and promotional strategies.

About Authors:
Swathi sree Karumuri^*, Venkata Naveen Kasagana
Department of Pharmaceutics,
Sankaralingam Bhuvaneswari College of Pharmacy, Anaikuttam,
Sivakasi - 626 130, Tamilnadu, India
*swathi.karumuri2011@gmail.com

Abstract:
New drugs pursuing novel delivery technologies with the objective of improving drug safety, efficacy and site Targeting in a cost effective way has been a challenging area of work for researchers. Their eminent work in the field of Novel technology has introduced many drug delivery methods to fulfil the requirements of pharmaceutical manufacturers and customers. Multiunit particulate systems (MUPS) are novel MDDS techniques that have gained importance, not only because of their ability to control drug release, but also for the modified drug-release profiles they facilitate. Similarly Acoustic targeted drug delivery (ATDD) is a method that uses ultrasound energy to enhance the transport of molecules into and/or across specific tissues. P.L.E.A.S.E. (Painless Laser Epidermal System) is a transdermal delivery device that uses a special laser source to create micro pores in the skin through which high molecular weight drugs are delivered painlessly in a highly controlled and accurate fashion. Oral delivery of insulin with increased lipophilicity across the gastrointestinal epithelium by the application of Eligen technology. Development of nanorobots with biosensors for medical target identification and drug delivery plays a prominent role in the diagnosis and treatment of Diseases. Gene delivery technology that turn off or on gene responsible for causing diseases like cancer and diabetes. The present article describes how Novel Drug delivery fulfils the Patient Needs on a Global Level and forms a key technology in the field of pharmaceuticals.

About Authors:
Venkata Naveen Kasagana*, Swathi sree Karumuri
Department of Pharmaceutics
Sankaralingam Bhuvaneswari College of Pharmacy, Anaikuttam,
Sivakasi - 626 130, Tamilnadu, India.
*naveen.kasagana@gmail.com

Abstract:
In the recent past global pharmaceutical markets has involved in developing the new Novel and Advanced drug delivery systems in a safe & cost effective manner. This resulted in the introduction of a variety of Controlled and Targeted drug delivery methods with ease of administration and patient compliance. The transition that took place by the introduction of nano technology in the field of pharmacy leads to the development of many intelligent drug delivery systems like Nano Beacon and Mini Beacons, Trojan horse Nano particles, MEMS & NEMS (Micro and Nano Electromechanical Systems). Cochleate delivery vehicles “A novel lipid-based system” represent a unique technology platform for oral and systemic delivery of drugs. BEMA (Bio Erodible Muco Adhesive Disc) drug delivery technology for prolonged acting action has contribution to the novel approach. Also a much awaited Non-injected insulin formulation “Nasal Insulin spray”, as a vaccine and also in the treatment of Type-II diabetes, provided a shift in the development of drug delivery systems. Duocap (Capsule-in-a-capsule), Electro capsule, Light up delivery monitoring technology (LDMT) are some of the controlled & targeted oral drug delivery systems, which provides a new way of formulating poorly soluble compounds and monitor the release rate of the drug. Apart from briefly describing the above technologies, the article includes the upcoming system of using Air as a barrier for Controlled release and application of medical devices as drug and their contribution to the World of pharmacy.

The Vice-Chair Person on behalf of District Health Society, Daman at Directorate of Medical & Health Services, Community Health Centre, Moti Daman is conducting a walk in interview for the posts of Paramedical staffs purely on short term contract basis.

Post: Pharmacist

India's ability to acquire a leadership position in the world, in the economic, demographic and intellectual fronts, would greatly depend on her ability to consolidate and take a vantage position in science & technology. Highly skilled S&T personnel adequately trained to face the challenges of inter-disciplinary and trans- disciplinary transformation of the biological and engineering sciences will command the workspace of tomorrow.

About Authors:
Satyanand tyagi^*, Raghvendra¹
*President, Tyagi Pharmacy Association & Scientific Writer,
Chattarpur, New Delhi, India-110074.
Prof. Satyanand Tyagi is a life time member of various pharmacy professional bodies like IPA, APTI and IPGA. He has published various research papers and review articles. His academic works include 45 Publications (37 Review Articles and 08 Research Articles of Pharmaceutical, Medicinal and Clinical Importance, published in standard and reputed National and International Pharmacy journals; Out of 45 publications, 10 are International Publications).
¹Department of Pharmaceutics, Aligarh College of Pharmacy,
Aligarh, U.P, India-202001.
*sntyagi9@yahoo.com, +91-9871111375 / 9582025220

ABSTRACT
Tak-875, a new treatment for type-2 diabetes, improves blood sugar control and is equally effective as glimepiride (Sulfonylurea, oral hypoglycaemic agent), but has a significantly lower risk of hypoglycaemia, according to a new study. It works by boosting the release of insulin from pancreatic beta cells when glucose and fatty acids rise in the blood, such as after a meal, which results in a fall in blood glucose levels. TAK-875 is a novel oral medication designed to enhance insulin secretion in a glucose dependent manner, which means that it has no effect on insulin secretion when glucose levels are normal, and as such has the potential to improve the control of blood sugar levels without the risk of hypoglycaemia. The pill belongs to a new class of treatments called GPR40 agonists, which activate a receptor that stimulates and regulates insulin production. New treatments are needed because of “the expected increase in the number of cases of Type 2 diabetes during the next few decades” and because some current drugs have “insufficient effect,” the researchers, led by Charles Burant at the University of Michigan Medical School, wrote in the study. Free fatty acid receptor 1 (FFA1), also known as G protein-coupled receptor 40 (GPR40), plays a vital role in stimulating and regulating the production of insulin. It works by boosting the release of insulin from pancreatic β-cells when glucose and fatty acids rise in the blood, such as after a meal. The release of insulin results in a fall in blood glucose levels. Drugs that activate the FFAR1 receptor have the potential to help diabetics release more insulin and improve control of blood glucose levels. This article gives an overview about this newly introduced drug TAK-875 and its role in treatment for type-2 diabetes.